Deutsche Bank AG Makes New $18.58 Million Investment in Oruka Therapeutics, Inc. $ORKA

Deutsche Bank AG acquired a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 195,204 shares of the company's stock, valued at approximately $18,578,000. Deutsche Bank AG owned approximately 0.32% of Oruka Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ORKA. Legal & General Group Plc acquired a new stake in Oruka Therapeutics during the second quarter worth approximately $28,000. BNP Paribas Financial Markets lifted its stake in Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock valued at $31,000 after buying an additional 2,306 shares during the period. Royal Bank of Canada boosted its holdings in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after buying an additional 365 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Oruka Therapeutics during the 4th quarter worth approximately $37,000. Finally, PNC Financial Services Group Inc. acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $39,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, Director Carl Dambkowski sold 22,417 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $70.13, for a total transaction of $1,572,104.21. Following the sale, the director owned 51,326 shares in the company, valued at $3,599,492.38. This represents a 30.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the firm's stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total value of $1,066,600.00. Following the completion of the transaction, the senior vice president directly owned 15,312 shares of the company's stock, valued at $1,633,177.92. The trade was a 39.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 83,116 shares of company stock worth $6,636,533 over the last ninety days. Company insiders own 23.49% of the company's stock.

Oruka Therapeutics Stock Performance

Shares of NASDAQ:ORKA opened at $107.96 on Friday. The company has a market capitalization of $7.15 billion, a P/E ratio of -53.18 and a beta of -0.34. Oruka Therapeutics, Inc. has a fifty-two week low of $14.34 and a fifty-two week high of $115.51. The company's 50-day moving average is $91.82 and its 200 day moving average is $65.23.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, research analysts predict that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. UBS Group increased their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a "buy" rating in a research note on Wednesday, July 1st. BTIG Research reissued a "buy" rating and set a $151.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Guggenheim reaffirmed a "buy" rating and issued a $200.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Weiss Ratings raised Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, July 15th. Finally, HC Wainwright reissued a "buy" rating and issued a $120.00 price objective on shares of Oruka Therapeutics in a research note on Monday, August 3rd. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $134.30.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source